Decreased vesicular acetylcholine transporter and α4β2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning
Identifieur interne : 009649 ( Main/Curation ); précédent : 009648; suivant : 009650Decreased vesicular acetylcholine transporter and α4β2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning
Auteurs : Mitchell Quinlivan [France, Australie] ; Sylvie Chalon [France] ; Jackie Vergote [France] ; Jasmine Henderson [Australie] ; Andrew Katsifis [Australie] ; Michael Kassiou [Australie] ; Denis Guilloteau [France]Source :
- Neuroscience letters [ 0304-3940 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Degeneration of cholinergic neurons is a well known characteristic of Alzheimer's disease (AD). Two radioligands were studied in a rat model of cholinergic degeneration to evaluate their potential efficacy for molecular imaging of AD. Following specific cholinergic-cell immunolesioning with 192 IgG-saporin (SAP), ex vivo autoradiography was performed with 123IBVM, a radioligand which targets the vesicular acetylcholine transporter (VAChT). Following the decay of 123I, the same animals had in vitro autoradiography performed with 125I-A-85380, a marker for nicotinic acetylcholine receptors (nAChRs). As expected significant, widespread decreases in 123IBVM uptake were observed in SAP treated animals. Moderate but significant reductions in 125I-A-85380 binding in the hippocampus (Hip) and cerebellum (Cbm) were also observed following SAP immunolesioning. The results with 123IBVM confirm and extend previous work investigating the uptake of radioiodinated IBVM in this animal model. The results with 125I-A-85380 are unique and are in contrast with work performed in this animal model with other nAChR radioligands, indicating the favourable properties of this radioligand for molecular imaging.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003D10
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002378
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003975
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :00A087
Links to Exploration step
Pascal:07-0182151Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Decreased vesicular acetylcholine transporter and α<sub>4</sub>β<sub>2</sub> nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning</title><author><name sortKey="Quinlivan, Mitchell" sort="Quinlivan, Mitchell" uniqKey="Quinlivan M" first="Mitchell" last="Quinlivan">Mitchell Quinlivan</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>37200 Tours</wicri:noRegion><wicri:noRegion>31 avenue Monge</wicri:noRegion><wicri:noRegion>37200 Tours</wicri:noRegion><orgName type="university">Université François-Rabelais de Tours</orgName><placeName><settlement type="city">Tours</settlement><region type="old region" nuts="2">Région Centre</region><region type="region" nuts="2">Centre-Val de Loire</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pharmacology, Bosch Bldg. D05, School of Medical Sciences and Bosch Institute, University of Sydney</s1><s2>Sydney, NSW 2006</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Radiopharmaceutical Research Institute, Bldg. 1, ANSTO, PMB 1</s1><s2>Menai, NSW 2234</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menai, NSW 2234</wicri:noRegion></affiliation></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>37200 Tours</wicri:noRegion><wicri:noRegion>31 avenue Monge</wicri:noRegion><wicri:noRegion>37200 Tours</wicri:noRegion><orgName type="university">Université François-Rabelais de Tours</orgName><placeName><settlement type="city">Tours</settlement><region type="old region" nuts="2">Région Centre</region><region type="region" nuts="2">Centre-Val de Loire</region></placeName></affiliation></author><author><name sortKey="Vergote, Jackie" sort="Vergote, Jackie" uniqKey="Vergote J" first="Jackie" last="Vergote">Jackie Vergote</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>37200 Tours</wicri:noRegion><wicri:noRegion>31 avenue Monge</wicri:noRegion><wicri:noRegion>37200 Tours</wicri:noRegion><orgName type="university">Université François-Rabelais de Tours</orgName><placeName><settlement type="city">Tours</settlement><region type="old region" nuts="2">Région Centre</region><region type="region" nuts="2">Centre-Val de Loire</region></placeName></affiliation></author><author><name sortKey="Henderson, Jasmine" sort="Henderson, Jasmine" uniqKey="Henderson J" first="Jasmine" last="Henderson">Jasmine Henderson</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pharmacology, Bosch Bldg. D05, School of Medical Sciences and Bosch Institute, University of Sydney</s1><s2>Sydney, NSW 2006</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Katsifis, Andrew" sort="Katsifis, Andrew" uniqKey="Katsifis A" first="Andrew" last="Katsifis">Andrew Katsifis</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Radiopharmaceutical Research Institute, Bldg. 1, ANSTO, PMB 1</s1><s2>Menai, NSW 2234</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menai, NSW 2234</wicri:noRegion></affiliation></author><author><name sortKey="Kassiou, Michael" sort="Kassiou, Michael" uniqKey="Kassiou M" first="Michael" last="Kassiou">Michael Kassiou</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>School of Medical Radiation Sciences, University of Sydney</s1><s2>NSW 1825</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>School of Chemistry, University of Sydney</s1><s2>NSW 2006</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Ramaciotti Centre for Brain Imaging, Brain and Mind Research Institute, University of Sydney</s1><s2>NSW 2006</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Tours</settlement><settlement type="city">Tours</settlement></placeName><orgName type="university">Université François-Rabelais de Tours</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0182151</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0182151 INIST</idno><idno type="RBID">Pascal:07-0182151</idno><idno type="wicri:Area/PascalFrancis/Corpus">003D10</idno><idno type="wicri:Area/PascalFrancis/Curation">002378</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003975</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003975</idno><idno type="wicri:doubleKey">0304-3940:2007:Quinlivan M:decreased:vesicular:acetylcholine</idno><idno type="wicri:Area/Main/Merge">00A087</idno><idno type="wicri:Area/Main/Curation">009649</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Decreased vesicular acetylcholine transporter and α<sub>4</sub>β<sub>2</sub> nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning</title><author><name sortKey="Quinlivan, Mitchell" sort="Quinlivan, Mitchell" uniqKey="Quinlivan M" first="Mitchell" last="Quinlivan">Mitchell Quinlivan</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Tours</settlement><settlement type="city">Tours</settlement></placeName><orgName type="university">Université François-Rabelais de Tours</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pharmacology, Bosch Bldg. D05, School of Medical Sciences and Bosch Institute, University of Sydney</s1><s2>Sydney, NSW 2006</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Radiopharmaceutical Research Institute, Bldg. 1, ANSTO, PMB 1</s1><s2>Menai, NSW 2234</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menai, NSW 2234</wicri:noRegion></affiliation></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>37200 Tours</wicri:noRegion><wicri:noRegion>31 avenue Monge</wicri:noRegion><wicri:noRegion>37200 Tours</wicri:noRegion><orgName type="university">Université François-Rabelais de Tours</orgName><placeName><settlement type="city">Tours</settlement><region type="old region" nuts="2">Région Centre</region><region type="region" nuts="2">Centre-Val de Loire</region></placeName></affiliation></author><author><name sortKey="Vergote, Jackie" sort="Vergote, Jackie" uniqKey="Vergote J" first="Jackie" last="Vergote">Jackie Vergote</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>37200 Tours</wicri:noRegion><wicri:noRegion>31 avenue Monge</wicri:noRegion><wicri:noRegion>37200 Tours</wicri:noRegion><orgName type="university">Université François-Rabelais de Tours</orgName><placeName><settlement type="city">Tours</settlement><region type="old region" nuts="2">Région Centre</region><region type="region" nuts="2">Centre-Val de Loire</region></placeName></affiliation></author><author><name sortKey="Henderson, Jasmine" sort="Henderson, Jasmine" uniqKey="Henderson J" first="Jasmine" last="Henderson">Jasmine Henderson</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pharmacology, Bosch Bldg. D05, School of Medical Sciences and Bosch Institute, University of Sydney</s1><s2>Sydney, NSW 2006</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Katsifis, Andrew" sort="Katsifis, Andrew" uniqKey="Katsifis A" first="Andrew" last="Katsifis">Andrew Katsifis</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Radiopharmaceutical Research Institute, Bldg. 1, ANSTO, PMB 1</s1><s2>Menai, NSW 2234</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menai, NSW 2234</wicri:noRegion></affiliation></author><author><name sortKey="Kassiou, Michael" sort="Kassiou, Michael" uniqKey="Kassiou M" first="Michael" last="Kassiou">Michael Kassiou</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>School of Medical Radiation Sciences, University of Sydney</s1><s2>NSW 1825</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>School of Chemistry, University of Sydney</s1><s2>NSW 2006</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Ramaciotti Centre for Brain Imaging, Brain and Mind Research Institute, University of Sydney</s1><s2>NSW 2006</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 avenue Monge</s1><s2>37200 Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Tours</settlement><settlement type="city">Tours</settlement></placeName><orgName type="university">Université François-Rabelais de Tours</orgName></affiliation></author></analytic><series><title level="j" type="main">Neuroscience letters</title><title level="j" type="abbreviated">Neurosci. lett.</title><idno type="ISSN">0304-3940</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neuroscience letters</title><title level="j" type="abbreviated">Neurosci. lett.</title><idno type="ISSN">0304-3940</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Cholinergic receptor</term><term>Density</term><term>Encephalon</term><term>IgG</term><term>Nicotinic receptor</term><term>Rat</term><term>Vesicular acetylcholine transporter</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Récepteur nicotinique</term><term>Densité</term><term>Encéphale</term><term>IgG</term><term>Récepteur cholinergique</term><term>Rat</term><term>Animal</term><term>Transporteur vésiculaire acétylcholine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Degeneration of cholinergic neurons is a well known characteristic of Alzheimer's disease (AD). Two radioligands were studied in a rat model of cholinergic degeneration to evaluate their potential efficacy for molecular imaging of AD. Following specific cholinergic-cell immunolesioning with 192 IgG-saporin (SAP), ex vivo autoradiography was performed with <sup>123</sup>IBVM, a radioligand which targets the vesicular acetylcholine transporter (VAChT). Following the decay of <sup>123</sup>I, the same animals had in vitro autoradiography performed with <sup>125</sup>I-A-85380, a marker for nicotinic acetylcholine receptors (nAChRs). As expected significant, widespread decreases in <sup>123</sup>IBVM uptake were observed in SAP treated animals. Moderate but significant reductions in <sup>125</sup>I-A-85380 binding in the hippocampus (Hip) and cerebellum (Cbm) were also observed following SAP immunolesioning. The results with <sup>123</sup>IBVM confirm and extend previous work investigating the uptake of radioiodinated IBVM in this animal model. The results with <sup>125</sup>I-A-85380 are unique and are in contrast with work performed in this animal model with other nAChR radioligands, indicating the favourable properties of this radioligand for molecular imaging.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 009649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Curation
|type= RBID
|clé= Pascal:07-0182151
|texte= Decreased vesicular acetylcholine transporter and α4β2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning
}}
| This area was generated with Dilib version V0.6.33. |  |